Extended Data Fig. 4: Acute and conditional ILC2 deletion does not impact intratumoural ILC1s, ILC3s or non-ILC lymphocytes.
From: IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer
a, NMUR1 expression on intratumoural immune cells in rIL-33-treated in Nmur1iCre-eGFP PDAC mice. b, c, Gating and frequency of all ILCs (b) and immune cells (c) in organs of rIL-33 and diphtheria toxin (DT)-treated Nmur1iCre-eGFPROSA26LSL-DTR and littermate control ROSA26LSL-DTR PDAC mice. d, Quantification of ILCs and immune cells in organs of rIL-33-treated Nmur1iCre-eGFP Ltbfl/fl and littermate control PDAC mice. e, Intratumoural KLRG1+ ILC2 gating, frequency and number (left), TLS density (middle) and immune cell frequency (right) in rIL-33-treated Il7rCreLtbfl/fl and littermate control IL7rCreLtb+/+ PDAC mice. Dotted line = putative TLS. Data collected 2 (b-e) and 4 (a) weeks after tumour implantation, pooled from ≥2 independent experiments with n ≥ 3 mice per group with consistent results. n = individual tumours or organs from individual mice analysed separately. Horizontal bars = median. In d, littermate control = Ltbfl/+ and Nmur1 iCre-eGFPLtbfl/+ combined. P values by two-way ANOVA with Sidak’s multiple comparison test (b, e right) and two-tailed Mann Whitney test (e left, middle).
